(Q48020223)

7 February 2018

title

Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. (English)

1 reference

7 February 2018

1 reference

1 reference

Levesque PE

1

1 reference

7 February 2018

Nieh PT

2

1 reference

7 February 2018

Zinman LN

3

1 reference

7 February 2018

Seldin DW

4

1 reference

7 February 2018

Libertino JA

5

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 June 1998

1 reference

7 February 2018

published in

Urology

1 reference

7 February 2018

volume

51

1 reference

7 February 2018

page(s)

978-984

1 reference

7 February 2018

issue

6

1 reference

7 February 2018

Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900025-9

7 January 2021

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900025-9

7 January 2021

Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900025-9

7 January 2021

The accuracy of CT in the staging of carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900025-9

7 January 2021

Staging pelvic lymphadenectomy for carcinoma of the prostate risk versus benefit

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900025-9

7 January 2021

Pelvic lymphadenectomy for staging clinically localized prostate cancer. Indications, complications, and results in 217 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900025-9

7 January 2021

Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900025-9

7 January 2021

Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900025-9

7 January 2021

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900025-9

7 January 2021

An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins: implications on the use of adjuvant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900025-9

7 January 2021

Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900025-9

7 January 2021

Improving survival for patients with prostate cancer diagnosed in the prostate-specific antigen ERA.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900025-9

7 January 2021

10.1016/S0090-4295(98)00025-9

Identifiers

DOI

1 reference

7 February 2018

PubMed ID

9609636

1 reference

7 February 2018